In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...